Ibrutinib (a selective covalent BTK inhibitor)19, nivolumab20 (a PD1 block) and lenalidomide (an immunomodulatory imide drug)21, showed promising response rates in refractory/recurrent PCNSL patients with good tolerability. This evidence concerns the gene BTK and primary central nervous system lymphoma.